

## **Corindus Evaluates Incorporating HeartFlow Technology with CorPath GRX System**

*Case series will explore feasibility of robotic assistance and FFRct*

**Waltham, MA – October 23, 2017** – Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support.

"We are pleased by this opportunity to incorporate the HeartFlow FFRct Analysis to advance our goal of improving patient outcomes in the cath lab through the synergistic use of this innovative non-invasive technology with our robotic platform," said Mark Toland, President and CEO of Corindus Vascular Robotics. "The integration of CorPath GRX with support tools that facilitate data-driven decision making, such as HeartFlow's technology, helps standardize and optimize patient care. By enabling standardized treatment across patients, this care model could play an essential role in reducing overall procedural costs for hospitals."

The case series will be conducted by Steven Almany, M.D., at Beaumont Hospital, Troy, in Troy, Michigan, and Srini Potluri, M.D. at The Heart Hospital Baylor Plano in Plano, Texas. An initial visit has already been conducted at both sites. A demonstration model will also be available to view at TCT 2017 in the Corindus booth #3021 from October 30 to November 1.

"The objective of this case series is to demonstrate how the integration of multiple cutting-edge technologies can potentially improve patient outcomes," said Dr. Potluri. "Incorporating the HeartFlow FFRct Analysis into CorPath's interventional cockpit combines an advanced pre-procedure planning tool with robotic precision to bring a new standard of care to patients."

CorPath GRX is the company's second-generation robotic-assisted PCI technology, bringing robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement. With independent and simultaneous robotic control of guide catheters, guidewires, and balloon/stent catheters, physicians have the capability to perform a range of procedures, including complex cases, from the cockpit.

The HeartFlow FFRct Analysis is a non-invasive technology that provides insight into both the extent of coronary artery disease and the impact of the disease on blood flow to the heart. Data from a patient's non-invasive coronary CT angiogram is securely uploaded from a hospital's system to the cloud. Following this data transfer, HeartFlow leverages deep learning to create a personalized digital 3D model of the patient's coronary arteries. It then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure web interface to the patient's physician, who uses the information to design a definitive, personalized treatment plan.

"We expect the results of this case series to impact how we approach future patient care," added Dr. Almany. "Adopting new and advanced tools to support procedure decision making has the potential to improve patient outcomes now and shift our thinking toward a high-tech cardiovascular care model for the future."

### **About Corindus Vascular Robotics**

[Corindus Vascular Robotics, Inc.](#) is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions (PCI). During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology

offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

#### **Forward Looking Statements**

*Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control.*

*Examples of such statements include statements that:*

- *the company's goal is to improve patient outcomes in the cath lab through the synergistic use of HeartFlow innovative technology with Corindus' robotic platform;*
- *the integration of CorPath GRX with support tools that facilitate data driven decision making, such as HeartFlow's technology, will help standardize and optimize patient care, enable standardized treatment across patients, and could play an essential role in reducing overall procedural costs for hospitals; and*
- *incorporating HeartFlow's interface into CorPath's interventional cockpit combines advanced pre-procedure planning tools with robotic precision to bring a new standard of care to patients.*

*Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at <http://www.corindus.com>.*

###

#### **Media Contacts:**

Corindus Vascular Robotics, Inc.  
Kate Stanton  
(508) 653-3335 ext. 200  
[kate.stanton@corindus.com](mailto:kate.stanton@corindus.com)

#### **Investor Contact:**

Lynn Pieper Lewis  
415-937-5402  
[ir@corindus.com](mailto:ir@corindus.com)